Research programme: CNS disorders therapeutics - (now Teva Pharmaceutical Industries)
Alternative Names: CEP-11124; CEP-16233; CEP-16795Latest Information Update: 27 Oct 2011
At a glance
- Originator Cephalon
- Class
- Mechanism of Action Histamine H3 receptor antagonists; Histamine H3 receptor inverse agonists; Serotonin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS disorders; Cognition disorders; Schizophrenia; Sleep disorders
Most Recent Events
- 16 Feb 2010 A lead compound from this research programme has entered clinical trials
- 04 Dec 2008 Preclinical development is ongoing
- 27 Mar 2007 Preclinical trials in Cognition disorders in USA (unspecified route)